Prevention of oral mucositis secondary to antineoplastic treatments in head and neck cancer by supplementation with oral glutamine.

Pachón Ibáñez, JerónimoPereira Cunill, José LuisOsorio Gómez, Guiovana FernandaIrles Rocamora, Jose AntonioSerrano Aguayo, PilarQuintana Ángel, BegoñaFuentes Pradera, JoséChaves Conde, ManuelOrtiz Gordillo, María JoséGarcía Luna, Pedro Pablo2023-01-252023-01-252018-02-27http://hdl.handle.net/10668/12460to evaluate the efficacy of glutamine in the prevention of the incidence of oral mucositis secondary to cancer therapies in patients with head and neck cancer (HNC). Secondary objectives were to know the incidence of odynophagia, interruptions of treatment and the requirements of analgesia and nasogastric tube. prospective cohort study of patients with squamous cell carcinoma of HNC treated with radiotherapy ± concomitant chemotherapy. We compared 131 patients receiving glutamine orally at a dose of 10 g/8 hours with 131 patients who did not receive it. patients not taking glutamine had a hazard ratio 1.78 times higher of mucositis (95% CI [1.01-3.16], p = 0.047). Regarding odynophagia, patients not taking glutamine had a hazard ratio 2.87 times higher (95% CI [1.62-5.18], p = 0.0003). The 19.8% of patients who did not take glutamine discontinued treatment versus6.9% of patients who took (p = 0.002). Regarding support requirements, 87.8% of patients without glutamine required analgesia versus 77.9% of patients with glutamine (p = 0.03) and nasogastric tube was indicated in 9.9% and 3.1% respectively (p = 0.02). oral glutamine in patients receiving cancer treatments for HNC prevents the incidence of oral mucositis and odynophagia, and decreases treatment interruptions and the use of analgesia and nasogastric tube.enAttribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/AdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Squamous CellChemoradiotherapyCohort StudiesDietary SupplementsFemaleGlutamineHead and Neck NeoplasmsHumansIncidenceMaleMiddle AgedProspective StudiesStomatitisPrevention of oral mucositis secondary to antineoplastic treatments in head and neck cancer by supplementation with oral glutamine.Prevención de la mucositis oral secundaria a los tratamientos antineoplásicos en el cáncer de cabeza y cuello mediante suplemento con glutamina oral.research article29756979open access10.20960/nh.14671699-5198https://doi.org/10.20960/nh.1467